Sellas Begins Screening AML Patients for Phase 3 Trial Testing Cancer Vaccine Galinpepimut-S
News
Sellas Life Sciences has started screening acute myeloid leukemia (AML) patients for a Phase 3 clinical trial evaluating its experimental vaccine galinpepimut-S (GPS) as a second-line maintenance therapy for patients who ... Read more